
Risk factors for atherosclerosis after anticancer treatment in childhood.

The assessment of lipid parameters and indicators of susceptibility to atherosclerosis in a group



of pediatric patients after anticancer treatment. Authors: Joanna Połubok, Olimpia Jasielska, Aleksandra Gonera, Marta Kozicka, Dorota Sęga-Pondel, Bernarda Kazanowska, Ewa Barg Wrocław Medical University, Poland

Background and objectives



Aim—to evaluate lipid profile in children after anticancer treatment

Materials and methods

Study group



44 patients; 3,25-16 years (mean 9.38± 3.57; median 9.09)



Solid tumors

>1 year after cessation of treatment

Evaluated parameters



cholesterol SDS, triglycerides SDS,
LDL-C SDS, HDL-C SDS,



• weight SDS, height SDS,

• BMI SDS.

Control group



Results

31 healthy children




- Statistical distances between groups
- Indicators of susceptibility to atherosclerosis

Evaluated			
narameters	Decreased	Normal	Increased

The risk factors of dyslipidemia (τ) in the study and in the control group

- Comparison of median in the cholesterol SDS, HDL-C SDS, LDL-C SDS, TG SDS
- Calculation of the statistical distance between the study group and the control group,



 E_i = median in the control group; O_i = median in the study group


increased risk of lipid disorders – positive sign (+) reduced risk of lipid disorders – negative sign (+)

parameters	Decreased	literinar	mereuseu
Total cholesterol SDS	1 (2,27%)	23 (52,27%)	20 (45,46%)
LDL-C SDS	0 (0%)	35 (79,55%)	9 (20,45%)
TG SDS	2 (4,55%)	31 (70,45%)	11 (25%)
HDL–C SDS	3 (6,82%)	36 (81,82%)	5 (11,36%)

Tab.2 Lipid parameters in study group

Compared parameter	Median		The risk factor of developing lipid disorders
	Study group	Control group	
Total cholesterol SDS	1,43	0,49	180,3
LDL-C SDS	0,83	0,60	8,82
TG-SDS	-0,17	-0,36	10,03

Elevated values of susceptibility to atherosclerosis in study group				
index Castelli (total cholesterol - HDL-C / HDL-C)	11.36%			
cholesterol C/HDL-C	11.36%			
LDL-C/HDL-C	20 55%			



Conclusions

1) Lipid disorders are a common complication among children after anticancer treatment.

2) Children after anticancer treatment require monitoring lipid parameters because of much higher risk of complications compared to healthy children.

